Get the Stockscreener App
4.35
4.82%
0.20
After Hours:
29.72
25.37
+583.22%
Relmada Therapeutics Inc stock is traded at $4.35, with a volume of 3.41M.
It is up +4.82% in the last 24 hours and up +4.07% over the past month.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.
See More
Previous Close:
$4.15
Open:
$4.16
24h Volume:
3.41M
Relative Volume:
3.17
Market Cap:
$319.00M
Revenue:
-
Net Income/Loss:
$-98.79M
P/E Ratio:
-1.3303
EPS:
-3.27
Net Cash Flow:
$-51.66M
1W Performance:
+7.14%
1M Performance:
+4.07%
6M Performance:
+521.52%
1Y Performance:
+1,133%
1-Day Range:
$4.15
$4.41
1-Week Range:
$3.98
$4.79
52-Week Range:
$0.2404
$5.12
Relmada Therapeutics Inc Stock (RLMD) Company Profile
Name
Relmada Therapeutics Inc
Sector
Industry
Phone
646 876 3459
Address
2222 PONCE DE LEON BLVD. 3RD FLOOR, CORAL GABLES, NY
Compare RLMD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| 3.03 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
2.95 | 4.38B | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
5.50 | 322.13M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
GOODO
Gladstone Commercial Corporation
|
20.77 | 372.90M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
5.07 | 185.60M | 0 | 0 | 0 | 0.00 |
|
DAVEW
Dave Inc
|
0.8118 | 0 | 0 | 0 | 0 | 0.00 |
Relmada Therapeutics Inc Stock (RLMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-19-25 | Upgrade | Mizuho | Neutral → Outperform |
| Dec-05-24 | Downgrade | Mizuho | Outperform → Neutral |
| Sep-17-24 | Upgrade | Jefferies | Hold → Buy |
| Jun-05-24 | Downgrade | Goldman | Neutral → Sell |
| Oct-14-22 | Downgrade | Goldman | Buy → Neutral |
| Oct-14-22 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-14-22 | Downgrade | Truist | Buy → Hold |
| Oct-13-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-18-21 | Initiated | Mizuho | Buy |
| May-20-21 | Resumed | Goldman | Buy |
| Oct-28-20 | Downgrade | Goldman | Buy → Neutral |
| Jul-14-20 | Initiated | Oppenheimer | Outperform |
| May-04-20 | Initiated | SunTrust | Buy |
| Apr-21-20 | Initiated | Goldman | Buy |
| Jan-27-20 | Initiated | Jefferies | Buy |
| Jan-10-20 | Initiated | SVB Leerink | Outperform |
| Dec-16-19 | Initiated | Guggenheim | Buy |
View All
Relmada Therapeutics Inc Stock (RLMD) Latest News
Will Relmada Therapeutics Inc. stock benefit from infrastructure spendingJuly 2025 Movers & Weekly Momentum Stock Picks - ulpravda.ru
Block Trades: Is Relmada Therapeutics Inc. stock supported by innovation pipeline2025 Trading Volume Trends & AI Powered Buy and Sell Recommendations - moha.gov.vn
Will Relmada Therapeutics Inc. (4E2) stock outperform energy sector in 2025Product Launch & Entry Point Confirmation Signals - ulpravda.ru
Is Relmada Therapeutics Inc. stock supported by strong cash flowsPortfolio Growth Summary & Entry Point Confirmation Alerts - ulpravda.ru
Momentum Shift: Why Relmada Therapeutics Inc. (4E2) stock benefits from AI revolution2025 Performance Recap & Low Risk Growth Stock Ideas - ulpravda.ru
Recap Report: Is Relmada Therapeutics Inc. stock supported by strong cash flowsBond Market & AI Enhanced Trading Alerts - ulpravda.ru
How supply chain issues affect Relmada Therapeutics Inc. stockJuly 2025 Macro Moves & Safe Entry Trade Reports - ulpravda.ru
RelmadaA New Contender To Watch In Bladder Cancer Drug Development? - RTTNews
Relmada Therapeutics (NASDAQ:RLMD) CFO Buys $48,059.80 in Stock - MarketBeat
Relmada Therapeutics updates executive contracts and increases salaries By Investing.com - Investing.com Australia
Relmada Therapeutics Amends Executive Employment Agreements - TipRanks
Relmada Therapeutics updates executive contracts and increases salaries - Investing.com
Relmada Therapeutics amends executive employment agreements - MSN
What analysts say about Relmada Therapeutics Inc stockMarket Insider Reports & Exceptional Profit Growth Tips - earlytimes.in
Aug Drivers: Can Relmada Therapeutics Inc stock outperform in 2025 bull marketAnalyst Upgrade & Safe Entry Trade Reports - moha.gov.vn
Comparing BeOne Medicines (NASDAQ:ONC) & Relmada Therapeutics (NASDAQ:RLMD) - Defense World
Taking on analysts’ expectations and winning: Relmada Therapeutics Inc (RLMD) - setenews.com
Relmada Therapeutics (RLMD) Price Target Increased by 900.00% to 10.20 - Nasdaq
Can Relmada Therapeutics Inc. stock hit analyst price targetsM&A Rumor & Technical Pattern Based Signals - Newser
Will Relmada Therapeutics Inc. (4E2) stock outperform value peersJuly 2025 Chart Watch & Fast Entry High Yield Stock Tips - Newser
Will Relmada Therapeutics Inc. stock deliver strong dividend growthGap Down & Risk Adjusted Buy and Sell Alerts - Newser
Relmada Therapeutics’ Earnings Call Highlights Clinical and Financial Success - MSN
Relmada’s bladder cancer therapy shows 92% complete response rate By Investing.com - Investing.com Nigeria
Relmada’s bladder cancer therapy shows 92% complete response rate - Investing.com India
Relmada Therapeutics Advances NDV-01 for Non-Muscle Invasive Bladder Cancer with Positive Phase 2 Follow-Up Data - Quiver Quantitative
Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology - GlobeNewswire
A History of Outperforming Analyst Forecasts and Beating the Odds: Relmada Therapeutics Inc (RLMD) - setenews.com
Why Relmada Therapeutics Inc. (4E2) stock stays resilientRecession Risk & Trade Opportunity Analysis - Newser
Relmada Therapeutics (RLMD) Stock Analysis Report | Financials & Insights - Benzinga
What risks investors should watch in Relmada Therapeutics Inc. stockTrade Ideas & Fast Moving Trade Plans - Newser
Relmada Therapeutics Inc. (US75955J4022.SG) Balance Sheet - Yahoo! Finance Canada
Relmada Therapeutics Announces $100 Million Underwritten Offering - globallegalchronicle.com
Relmada Therapeutics Inc 4E2 Stock Analysis and ForecastVolume Analysis Techniques & Rapid Portfolio Trading - earlytimes.in
Relmada Therapeutics, Inc.Common Stock (NQ: RLMD - Markets Financial Content
Views of Wall Street’s Leading Experts on Relmada Therapeutics Inc - Setenews
Relmada Therapeutics Inc. (RLMD) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Relmada cut to neutral by Mizuho on Phase 3 study failure - MSN
Relmada Therapeutics, Inc. (RLMD) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
How risky is Relmada Therapeutics Inc. stock now2025 Key Lessons & Growth Focused Entry Reports - newser.com
How Relmada Therapeutics Inc. (4E2) stock trades in high volatilityEarnings Overview Report & Risk Controlled Daily Trade Plans - newser.com
This Stock Is Up 704% in 2025 But Has No Products to Its Name - inkl
Will Relmada Therapeutics Inc. stock sustain high P E ratiosCEO Change & Consistent Growth Equity Picks - newser.com
Is Relmada Therapeutics Inc. showing signs of accumulationQuarterly Portfolio Report & AI Enhanced Trade Execution Alerts - newser.com
Relmada Therapeutics Inc Stock (RLMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):